Emerging therapies in dyslipidaemias

Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several new lipid-lowering agents are currently in phase 3 clinical trials to evaluate their clinical effects, and more are in development. The use of combination therapies targeting different pathways can increase the effectiveness of treatment.PMID:37716371 | DOI:10.1016/j.vph.2023.107229
Source: Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research